Helping Not-For-Profits fundraise through a Shared Raffle
Learn more hereThis is a Bolsta Shared Raffle Campaign Fundraiser
Simply buy raffle tickets here, and not only will you be supporting a great cause, you'll also have a chance to win some great prizes!
IDFA is a national non-profit organization that offers education, awareness, and advocacy for Australians with primary or secondary immunodeficiency.
Your donation will support IDFA's advocacy work around Newborn Screening Awareness for Severe Combined Immunodeficiency (SCID).
Severe Combined Immunodeficiency (SCID) is a life-threatening genetic condition in which affected babies are unable to fight even simple infections. SCID is often referred to as the ‘bubble boy disease’ highlighting the threat of exposure to germs and is considered an immunological emergency. Without appropriate timely treatment, most children die before the age of 2 years. If diagnosed early and then treated early, SCID can be entirely curable. Early diagnosis is possible with universal SCID newborn screening.
SCID screening costs less than $10 per child. Over half of Australia’s states and territories now have SCID Newborn Screening testing available for families. IDFA is calling for the implementation of routine SCID Newborn Screening in South Australia and Tasmania.
Your donation will help IDFA raise awareness about SCID, promote access to early testing, and support community members suffering or caring for someone with SCID through support groups.
1st Prize
$20,000 CashDraw Date
31 May 2024Ticket Cost
$5
Major Prize is $20,000 Cash. Second prize is $2,000 cash. Third prize is $1,000 Cash.
All proceeds from this raffle are collected for charitable or benevolent not-for-profit purposes by Bolsta Foundation Limited (ABN 75 641 134 974), under NSW Charitable Fundraising Authority CFN/26189
Payment In Progress...
Standard tickets : 1 Bonus tickets : 0
A guaranteed 50% of your ticket purchase goes directly to The Immune Deficiency Foundation of Australia Limited
Raffle Drawn 31st of May 2024